TLR4 Polymorphisms (896A>G and 1196C>T) Affect the Predisposition to Diabetic Nephropathy in Type 2 Diabetes Mellitus

References

• Tillin T, Sattar N, Godsland IF, Hughes AD, Chaturvedi N, Forouhi NG. Ethnicity-specific obesity cut-points in the development of type 2 diabetes - a prospective study including three ethnic groups in the United Kingdom. Diabet Med. 2015;32(2):226–234. doi:10.1111/dme.12576
   PubMedGoogle Scholar
• Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Abingdon). 2014;42(12):698–702. doi:10.1016/j.mpmed.2014.09.007
   PubMedGoogle Scholar
• World Health Organization. Diabetes country profiles. World Health Organization; 2016. Available from: http://www.who.int/diabetes/country-profiles/irn_en.pdf?ua=1. Accessed March 25, 2020.
   Google Scholar
• Haghdoost AA, Rezazadeh-Kermani M, Sadghirad B, Baradaran HR. Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. East Mediterr Health J. 2009;15(3):591–599. doi:10.26719/2009.15.3.591
   PubMedGoogle Scholar
• Habibzadeh F, Yadollahie M, Roshanipoor M, Haghighi AB. Prevalence of atrial fibrillation in a primary health care centre in Fars Province, Islamic Republic of Iran. East Mediterr Health J. 2004;10(1–2):147–151.
   PubMedGoogle Scholar
• Habiba NM, Fulda KG, Basha R, et al. Correlation of lipid profile and risk of developing type 2 diabetes mellitus in 10–14 year old children. Cell Physiol Biochem. 2016;39(5):1695–1704. doi:10.1159/000447870
   PubMedGoogle Scholar
• Kalsi DS, Chopra J, Sood A. Association of lipid profile test values, type-2 diabetes mellitus, and periodontitis. Indian J Dent. 2015;6(2):81–84. doi:10.4103/0975-962X.157270
   PubMedGoogle Scholar
• Haase CL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R, Cholesterol HDL. Risk of type 2 diabetes: a mendelian randomization study. Diabetes. 2015;64(9):3328–3333. doi:10.2337/db14-1603
   PubMedGoogle Scholar
• Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol. 2003;41(7):1071–1077. doi:10.1016/S0735-1097(03)00088-3
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334. doi:10.1001/jama.286.3.327
   PubMed Web of Science ®Google Scholar
• Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med. 2004;21(3):203–207. doi:10.1046/j.1464-5491.2003.01030.x
   PubMed Web of Science ®Google Scholar
• Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813–823. doi:10.2337/diacare.27.3.813
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2008;19(1):10–16. doi:10.1016/j.tem.2007.10.004
   PubMedGoogle Scholar
• Manolakis AC, Kapsoritakis AN, Tiaka EK, et al. TLR4 gene polymorphisms: evidence for protection against type 2 diabetes but not for diabetes-associated ischaemic heart disease. Eur J Endocrinol. 2011;165(2):261–267. doi:10.1530/EJE-11-0280
   PubMedGoogle Scholar
• Rudofsky G, Reismann P, Witte S, et al. Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes. Diabetes Care. 2004;27(1):179–183. doi:10.2337/diacare.27.1.179
   PubMed Web of Science ®Google Scholar
• Rallabhandi P, Bell J, Boukhvalova MS, et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol. 2006;177(1):322–332. doi:10.4049/jimmunol.177.1.322
   PubMed Web of Science ®Google Scholar
• Peterson JM, Mart R, Bond CE. Effect of obesity and exercise on the expression of the novel myokines, Myonectin and Fibronectin type III domain containing 5. PeerJ. 2014;2:e605. doi:10.7717/peerj.605
   PubMed Web of Science ®Google Scholar
• Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol. 2016;12(1):13–26. doi:10.1038/nrneph.2015.175
   PubMed Web of Science ®Google Scholar
• Jialal I, Kaur H, Devaraj S. Toll-like receptor status in obesity and metabolic syndrome: a translational perspective. J Clin Endocrinol Metab. 2014;99(1):39–48. doi:10.1210/jc.2013-3092
   PubMed Web of Science ®Google Scholar
• Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014;7:587–591. doi:10.2147/DMSO.S67400
   PubMedGoogle Scholar
• Fathya WM, Solimana MA, Raghebb A, Al Ashramc GH. Study of toll-like receptor 4 in type 2 diabetic patients with or without nephropathy. Menoufia Med J. 2016;29(1):167–173. doi:10.4103/1110-2098.179009
   Google Scholar
• Cai H, Cai J, Tao G. Association of toll-like receptor 4 polymorphisms with type 2 diabetes mellitus. APMIS. 2013;121(7):605–611. doi:10.1111/apm.12027
   PubMedGoogle Scholar
• Peng D, Wang J, Pan J, et al. Lack of association between TLR4 genetic polymorphisms and diabetic nephropathy in a Chinese population. Biomed Res Int. 2014;2014:704167. doi:10.1155/2014/704167
   PubMedGoogle Scholar
• Yin YW, Wang Q, Sun QQ, Hu AM, Liu HL. Toll-like receptor 4 gene Asp299Gly and Thr399Ile polymorphisms in type 2 diabetes mellitus: a meta-analysis of 15,059 subjects. Diabetes Res Clin Pract. 2015;107(3):338–347. doi:10.1016/j.diabres.2015.01.008
   PubMedGoogle Scholar
• American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S124–S138. doi:10.2337/dc19-S011
   PubMed Web of Science ®Google Scholar
• Tajik N, Nasiri MR, Jafari M, et al. Association between toll-like receptor 4 (TLR4) genetic polymorphisms and susceptibility to pulmonary tuberculosis. Razi J Med Sci. 2010;16(68):19–26.
   Google Scholar
• Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22(15):1928–1929. doi:10.1093/bioinformatics/btl268
   PubMed Web of Science ®Google Scholar
• Lin M, Yiu WH, Wu HJ, et al. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol. 2012;23(1):86–102. doi:10.1681/ASN.2010111210
   PubMed Web of Science ®Google Scholar
• Illig T, Bongardt F, Schopfer A, et al. The endotoxin receptor TLR4 polymorphism is not associated with diabetes or components of the metabolic syndrome. Diabetes. 2003;52(11):2861–2864. doi:10.2337/diabetes.52.11.2861
   PubMedGoogle Scholar
• Liu F, Lu W, Qian Q, Qi W, Hu J, Feng B. Frequency of TLR 2, 4, and 9 gene polymorphisms in Chinese population and their susceptibility to type 2 diabetes and coronary artery disease. J Biomed Biotechnol. 2012;2012:373945. doi:10.1155/2012/373945
   PubMedGoogle Scholar
• Bagarolli RA, Saad MJ, Saad ST. Toll-like receptor 4 and inducible nitric oxide synthase gene polymorphisms are associated with type 2 diabetes. J Diabetes Complications. 2010;24(3):192–198. doi:10.1016/j.jdiacomp.2009.03.003
   PubMedGoogle Scholar
• Kolek MJ, Carlquist JF, Muhlestein JB, et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J. 2004;148(6):1034–1040. doi:10.1016/j.ahj.2004.05.049
   PubMedGoogle Scholar
• Erridge C, Stewart J, Poxton IR. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med. 2003;197(12):1787–1791. doi:10.1084/jem.20022078
   PubMedGoogle Scholar
• Orr JS, Puglisi MJ, Ellacott KL, Lumeng CN, Wasserman DH, Hasty AH. Toll-like receptor 4 deficiency promotes the alternative activation of adipose tissue macrophages. Diabetes. 2012;61(11):2718–2727. doi:10.2337/db11-1595
   PubMed Web of Science ®Google Scholar
• Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 2014;1842(3):446–462. doi:10.1016/j.bbadis.2013.05.017
   PubMed Web of Science ®Google Scholar
• Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 2003;26(11):3153–3159. doi:10.2337/diacare.26.11.3153
   PubMed Web of Science ®Google Scholar
• Mahdavi M, Fallah Z, Kelishadi R. Expression of Toll-Like receptors in metabolic syndrome: a systematic review. J Basic Res Med Sci. 2018;5(3):52–56. doi:10.29252/jbrms.5.3.52
   Google Scholar
• Abbas SA, Raza ST, Mir SS, et al. Role of variants rs5030717 and rs5030718 of TLR4 in the risk prediction of nephropathy, hypertension and dyslipidaemia in type 2 diabetes mellitus. Br J Biomed Sci. 2018;75(4):163–168. doi:10.1080/09674845.2018.1477033
   PubMed Web of Science ®Google Scholar
• Kolz M, Baumert J, Muller M, et al. Association between variations in the TLR4 gene and incident type 2 diabetes is modified by the ratio of total cholesterol to HDL-cholesterol. BMC Med Genet. 2008;9(1):9. doi:10.1186/1471-2350-9-9
   PubMedGoogle Scholar
• Zhu YJ, Wang C, Song G, Zang SS, Liu YX, Li L. Toll-like receptor-2 and −4 are associated with hyperlipidemia. Mol Med Rep. 2015;12(6):8241–8246. doi:10.3892/mmr.2015.4465
   PubMedGoogle Scholar
• Qing YF, Zhou JG, Zhang QB, et al. Association of TLR4 Gene rs2149356 polymorphism with primary gouty arthritis in a case-control study. PLoS One. 2013;8(5):e64845. doi:10.1371/journal.pone.0064845
   PubMed Web of Science ®Google Scholar
• Stadler K, Goldberg IJ, Susztak K. The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease. Curr Diab Rep. 2015;15(7):40. doi:10.1007/s11892-015-0611-8
   PubMed Web of Science ®Google Scholar
• Rutledge JC, Ng KF, Aung HH, Wilson DW. Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol. 2010;6(6):361–370. doi:10.1038/nrneph.2010.59
   PubMed Web of Science ®Google Scholar
• Palazhy S, Viswanathan V. Lipid abnormalities in type 2 diabetes mellitus patients with overt nephropathy. Diabetes Metab J. 2017;41(2):128–134. doi:10.4093/dmj.2017.41.2.128
   PubMedGoogle Scholar
• Kumsaiyai W. The impact of human adipose tissue on metabolic dysfunction in obesity and type 2 diabetes mellitus. Unpublished: Warwick Medical School; 2014.
   Google Scholar
• Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832–1839. doi:10.2337/db05-1620
   PubMed Web of Science ®Google Scholar
• Hirano T. Abnormal lipoprotein metabolism in diabetic nephropathy. Clin Exp Nephrol. 2014;18(2):206–209. doi:10.1007/s10157-013-0880-y
   PubMed Web of Science ®Google Scholar
• Anders HJ, Schlondorff D. Toll-like receptors: emerging concepts in kidney disease. Curr Opin Nephrol Hypertens. 2007;16(3):177–183. doi:10.1097/MNH.0b013e32803fb767
   PubMedGoogle Scholar
• Zhao H, Perez JS, Lu K, George AJ, Ma D. Role of Toll-like receptor-4 in renal graft ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2014;306(8):F801–F811. doi:10.1152/ajprenal.00469.2013
   PubMed Web of Science ®Google Scholar
• Kuwabara T, Mori K, Mukoyama M, et al. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Diabetologia. 2012;55(8):2256–2266. doi:10.1007/s00125-012-2578-1
   PubMed Web of Science ®Google Scholar